產(chǎn)品描述: | Cyclo(-RGDfK) is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM. Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface |
靶點(diǎn): |
αvβ3:0.94 nM (IC50);Integrin |
參考文獻(xiàn): |
1. Simecek J, et al. Benefits of NOPO as chelator in gallium-68 peptides, exemplified by preclinical characterization of (68)Ga-NOPO-c(RGDfK). Mol Pharm. 2014 May 5;11(5):1687-95. 2. Lopez-Rodriguez V, et al. Preparation and preclinical evaluation of (66)Ga-DOTA-E(c(RGDfK))2 as a potential theranostic radiopharmaceutical. Nucl Med Biol. 2015 Feb;42(2):109-14. |
溶解性: |
DMSO : 125 mg/mL (207.07 mM; Need ultrasonic) H2O : 50 mg/mL (82.83 mM; Need ultrasonic) |
保存條件: |
2-8℃ |
配置溶液濃度參考: |
|
1mg |
5mg |
10mg |
1 mM |
1.657 ml |
8.283 ml |
16.565 ml |
5 mM |
0.331 ml |
1.657 ml |
3.313 ml |
10 mM |
0.166 ml |
0.828 ml |
1.657 ml |
50 mM |
0.033 ml |
0.166 ml |
0.331 ml |
|
注意: |
部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。 |